Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
|Articles|October 1, 2008
- Psychiatric Times Vol 25 No 11
- Volume 25
- Issue 11
Broken Mug
Author(s)Richard M. Berlin, MD
Advertisement
By Richard M. Berlin, MD
Articles in this issue
about 18 years ago
Theoretical Models of Health Behaviorabout 18 years ago
The Differential Diagnosis of Childhood Developmental Disordersabout 18 years ago
Wrong Choicesabout 18 years ago
Coping With Obscene Phone Callsabout 18 years ago
Cyber Bullyingabout 18 years ago
The Dementias: Neuropsychiatric Syndromes of the 21st Centuryabout 18 years ago
Acupuncture: An Updateabout 18 years ago
Antipsychotics in Dementia: Evidence of Risk Mountsabout 18 years ago
Advances in Neuroimaging: Impact on Psychiatric PracticeAdvertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Clozapine Remains Underused After REMS Elimination: A Conversation With Jose Rubio, MD, PhD
3
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
4
Phase 1 Clinical Studies Completed: NTX-253 for the Treatment of Schizophrenia
5